As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Sotera Health Company (NASDAQ:SHC) and its peers.

Sotera Health Company trades at $19.02 per share and has stayed right on track with the overall market, gaining 11.3% over the last six months. At the same time, the S&P 500 has returned 13.1%.

Sotera Health’s second quarter was marked by broad-based growth across its business units, which drove a positive market reaction. Management credited robust demand in both core sterilization (Sterigenics) and isotope supply (Nordion), coupled with improved customer engagement at Nelson Labs, for the outperformance. CEO Alton Shader highlighted that "Sterigenics built on strong momentum from Q1, delivering 7% constant currency revenue growth," while Nordion benefited from favorable Cobalt-60 shi

Revenue hit $321 million with adjusted EPS up 30% year over year.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points.

US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index’s 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), […]

Healthcare services company Sotera Health (NASDAQ:SHC) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.2% year on year to $321.4 million. The company expects the full year’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.26 per share was 8.7% above analysts’ consensus estimates.

Sotera Health Company’s Q2 2026 results, released on August 6, showed revenue rising to US$321.38 million and net income to US$53.64 million, with earnings per share from continuing operations increasing to US$0.19 from US$0.03 a year earlier. Management’s decision to raise full-year guidance after broad-based growth across Sterigenics, Nordion and Nelson Labs highlights improving profitability supported by pricing, volume mix and operational execution. We’ll now examine how Sotera Health’s...

Sotera Health (NASDAQ:SHC) reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook. The company also marked a leadership transition during the quarter. Alton Shader be

Moby summary of Sotera Health Company's Q2 2026 earnings call

Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sotera Health (SHC) delivered earnings and revenue surprises of +8.33% and +3.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare services company Sotera Health (NASDAQ:SHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.2% year on year to $321.4 million. The company expects the full year’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.26 per share was 8.7% above analysts’ consensus estimates.

O’Keeffe Stevens Advisory, an investment advisory firm, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. During Q2 2026, the market experienced notable dispersion between perceived AI losers and winners. The firm has made investments early in AI infrastructure companies, which yielded gains during market repricing. The second quarter […]

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.